Form 4: MannKind Officer Granted Performance Equity

MannKind's Chief People & Workplace Officer, Stuart A. Tross, received grants of 221,000 performance-based restricted stock units and 217,000 employee stock options.

Summary

• Stuart A. Tross, MannKind Corp's Chief People & Workplace Officer, was granted 221,000 performance-based Restricted Stock Units (RSUs) on March 23, 2026.
• Each RSU represents a contingent right to receive one share of MNKD common stock.
• The RSUs will vest on January 15, 2029, with the number of shares delivered determined by MannKind's Total Shareholder Return (TSR) percentile ranking relative to the Russell 3000 Pharmaceutical & Biotechnology Index over the period from April 1, 2026, to December 31, 2028.
• Payout for RSUs ranges from 0% of target (less than 25th percentile TSR) to 300% maximum (90th percentile or higher TSR), with interpolation for intermediate rankings.
• Mr. Tross also received a grant of 217,000 Employee Stock Options on March 23, 2026, with an exercise price of $2.44 per share.
• These stock options will begin vesting 25% on March 23, 2027, and thereafter 1/16th quarterly, expiring on March 23, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While it's a routine compensation disclosure, the performance-based nature of the RSUs aligns executive incentives with shareholder value creation, which is generally favorable.

Positives

• The equity grants align the Chief People & Workplace Officer's financial interests directly with the long-term performance and shareholder value creation of MannKind Corp.
• The performance-based nature of the RSUs incentivizes outperformance relative to an industry peer group, potentially driving stronger strategic execution.

Negatives

• The grants do not represent an immediate cash benefit to the executive or the company.
• The ultimate value of the performance-based RSUs is uncertain and dependent on future stock performance relative to a benchmark, which introduces risk for the executive.

Risks

• The vesting of performance-based restricted stock units is contingent on MannKind's Total Shareholder Return (TSR) relative to the Russell 3000 Pharmaceutical & Biotechnology Index, meaning the executive may receive 0% of the target shares if performance is poor.
• The value of the stock options is dependent on MannKind's stock price exceeding the exercise price of $2.44 per share in the future.

Future Outlook

The performance-based nature of the RSU grant, with a measurement period extending to December 31, 2028, indicates a strategic focus on long-term shareholder return relative to industry peers. The vesting schedule for stock options also extends over several years, suggesting a commitment to retaining and incentivizing executive performance over the medium term.

Industry Context

StockSavvy.ai notes that performance-based equity grants, particularly those tied to relative Total Shareholder Return (TSR) against a relevant industry index like the Russell 3000 Pharmaceutical & Biotechnology Index, are a common and effective practice in the biotechnology and pharmaceutical sectors. This approach is designed to align executive compensation with competitive market performance and shareholder value creation.

Comparison to Industry Standards

• The use of performance-based Restricted Stock Units (RSUs) tied to relative Total Shareholder Return (TSR) against an industry index (Russell 3000 Pharmaceutical & Biotechnology Index) is a standard and widely accepted practice for executive compensation in the biotechnology and pharmaceutical industries.
• This compensation structure is comparable to those seen at peer companies within the biotech/pharma space, such as Amgen, Gilead Sciences, or Biogen, which frequently utilize similar long-term incentive plans to motivate executives and align their interests with those of shareholders.

Stakeholder Impact

• Shareholders: The performance-based nature of the equity grants aims to align executive incentives with shareholder value creation, potentially benefiting long-term investors.
• Employees (Stuart A. Tross): The grants provide significant long-term incentive compensation, contingent on company and stock performance.

Next Steps

• MannKind's Total Shareholder Return (TSR) will be measured from April 1, 2026, to December 31, 2028, relative to the Russell 3000 Pharmaceutical & Biotechnology Index to determine RSU payout.
• The first tranche of stock options will vest on March 23, 2027, with subsequent quarterly vesting.

Key Dates

Recommendation

This Form 4 details a routine equity grant to a key executive, which is a standard compensation practice. It does not provide new information on the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. The grants align executive incentives with shareholder value but do not inherently signal a buy or sell opportunity.

Keywords

MannKind, MNKD, Restricted Stock Units, RSU, Stock Options, Executive Compensation, Form 4, Insider Transaction, Equity Grant, Performance-based compensation